The estimated Net Worth of Sebastian J Bufalino is at least 1.09 百万$ dollars as of 27 March 2014. Sebastian Bufalino owns over 21,600 units of Baxter International stock worth over 1,094,651$ and over the last 12 years Sebastian sold BAX stock worth over 0$.
Sebastian has made over 2 trades of the Baxter International stock since 2013, according to the Form 4 filled with the SEC. Most recently Sebastian exercised 21,600 units of BAX stock worth 828,360$ on 27 March 2014.
The largest trade Sebastian's ever made was exercising 24,000 units of Baxter International stock on 20 May 2013 worth over 836,400$. On average, Sebastian trades about 2,533 units every 17 days since 2013. As of 27 March 2014 Sebastian still owns at least 27,875 units of Baxter International stock.
You can see the complete history of Sebastian Bufalino stock trades at the bottom of the page.
Sebastian's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Over the last 22 years, insiders at Baxter International have traded over 966,809,165$ worth of Baxter International stock and bought 178,227 units worth 6,261,495$ . The most active insiders traders include Point Llc Loeb Daniel S Third、Michael F Mahoney、Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of 3,609,738$. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth 2,397,019$.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: